News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,613 Results
Type
Article (14897)
Company Profile (299)
Press Release (266411)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79834)
Career Advice (162)
Deals (13336)
Drug Delivery (39)
Drug Development (50699)
Employer Resources (31)
FDA (5836)
Job Trends (5167)
News (145074)
Policy (10071)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21761)
ALS (125)
Alzheimer's disease (1032)
Antibody-drug conjugate (ADC) (241)
Approvals (6031)
Artificial intelligence (259)
Autoimmune disease (113)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (344)
Cancer (3130)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (218)
CDC (5)
Cell therapy (564)
Cervical cancer (14)
Clinical research (43671)
Collaboration (1151)
Company closure (2)
Compensation (596)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (553)
Cystic fibrosis (112)
Data (4325)
Denatured (15)
Depression (92)
Diabetes (255)
Diagnostics (1379)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (188)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (216)
Earnings (31646)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51668)
Executive appointments (622)
FDA (7590)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (982)
Gene editing (182)
Generative AI (21)
Gene therapy (490)
GLP-1 (504)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6611)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (40)
Indications (66)
Infectious disease (1205)
Inflammatory bowel disease (156)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7345)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (420)
Lymphoma (249)
Machine learning (24)
Management (7)
Manufacturing (376)
MASH (130)
Medical device (2662)
Medtech (2671)
Mergers & acquisitions (6615)
Metabolic disorders (725)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (231)
Neuropsychiatric disorders (70)
Neuroscience (1954)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (330)
Peanut (43)
People (26655)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15475)
Phase 2 (20291)
Phase 3 (12821)
Pipeline (3263)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (651)
Real estate (1448)
Recruiting (12)
Regulatory (9899)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (183)
Series B (136)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (334)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (52)
Last 7 days (339)
Last 30 days (1165)
Last 365 days (17847)
2026 (1702)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18255)
Australia (3111)
California (7079)
Canada (1839)
China (774)
Colorado (247)
Connecticut (252)
Delaware (235)
Europe (39168)
Florida (903)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (161)
Iowa (8)
Japan (224)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5588)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1648)
New Mexico (13)
New York (1763)
North Carolina (827)
North Dakota (6)
Northern California (3477)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1280)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2808)
Tennessee (40)
Texas (907)
United States (23351)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,613 Results for "vigeo therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Vigeo Therapeutics Provides Clinical Update on VT1021 Treatment of GBM Expansion Patient
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, is pleased to announce that a complete response patient (CR) in Glioblastoma (GBM) cohort from first in human study VT1021-01 (NCT03364400) has now completed 3 full years of dosing with VT1021.
July 13, 2023
·
2 min read
Genetown
Vigeo Therapeutics New Immune Profiling and Biomarker Data Ph I/II Expansion study in GBM Patients
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, announced encouraging new data from its phase I/II expansion study evaluating single-agent activity of VT1021 in patients with recurrent glioblastoma.
May 25, 2023
·
3 min read
Drug Development
Vigeo Therapeutics will present New Clinical and Immune Profiling Data from Ph I/II Expansion study in GBM Patients in ASCO Poster Oral Session
Vigeo Therapeutics today announced new data from its Phase I/II expansion study evaluating single-agent activity of VT1021 in patients with recurrent glioblastoma (rGBM).
June 2, 2023
·
3 min read
Biotech Bay
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and Vigeo Therapeutics -- The Global Coalition for Adaptive Research (GCAR) in collaboration with Biohaven and Vigeo Therapeutics, today announced the activation of Biohaven’s troriluzole and Vigeo’s VT1021 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment).
July 6, 2022
·
8 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Drug Development
Vigeo Therapeutics Provides Clinical Update for Lead Asset VT1021 and Welcomes New Chief Executive Officer
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, announced completion of the Phase 1/2 dose expansion studies evaluating its lead asset VT1021 in recurrent glioblastoma and pancreatic cancer.
September 21, 2021
·
4 min read
Drug Development
Vigeo Therapeutics Announces New Phase 1/2 Data from its Expansion Study of VT1021 at the Society of NeuroOncology’s 2021 Annual Meeting
Vigeo Therapeutics today announced new clinical data from its Phase 1/2 expansion study evaluating the single-agent activity of VT1021 in subjects with recurrent glioblastoma (rGBM).
November 16, 2021
·
3 min read
Press Releases
Altamira Therapeutics to Present at mRNA-Based Therapeutics Summit
January 26, 2026
·
4 min read
Genetown
Vigeo Therapeutics Announces New Phase 1/2 Data from its Expansion Study of VT1021 at the Society for Immunotherapy of Cancer’s 2021 Annual Meeting
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced new clinical data from its Phase 1/2 expansion study evaluating the single-agent activity of VT1021 in subjects with pancreatic cancer and recurrent glioblastoma (rGBM).
November 9, 2021
·
4 min read
Genetown
Vigeo Therapeutics to Present New Phase 1/2 VT1021 Data from its Pancreatic Cancer Expansion Study at the Society for Immunotherapy of Cancer’s 2021 Annual Meeting
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced it will have two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 2021 Annual Meeting, taking place from November 10-14, 2021.
October 1, 2021
·
2 min read
1 of 28,162
Next
